Browsing byAuthorIrwig, L

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 11 to 19 of 19< previous 
Issue DateTitleAuthor(s)
2018-01-01Legacy effects of statins on cardiovascular and all-cause mortality: A meta-analysisNayak, A; Hayen, A; Zhu, L; McGeechan, K; Glasziou, P; Irwig, L; Doust, J; Gregory, G; Bell, K
2020-11Mammography screening for breast cancer-the UK Age trial.Bell, KJL; Irwig, L; Nickel, B; Hersch, J; Hayen, A; Barratt, A
2011-01-29Monitoring adherence to drug treatment by using change in cholesterol concentration: Secondary analysis of trial dataBell, KJL; Kirby, A; Hayen, A; Irwig, L; Glasziou, P
2011-12-10Optimizing the frequency of follow-up visits for patients treated for localized primary cutaneous melanomaTurner, RM; Bell, KJL; Morton, RL; Hayen, A; Francken, AB; Howard, K; Armstrong, B; Thompson, JF; Irwig, L
2012-01-01The potential value of monitoring bone turnover markers among women on alendronateBell, KJL; Hayen, A; Irwig, L; Hochberg, MC; Ensrud, KE; Cummings, SR; Bauer, DC
2018-04-01Prognostic impact of systolic blood pressure variability in people with diabetesBell, KJL; Azizi, L; Nilsson, PM; Hayen, A; Irwig, L; Östgren, CJ; Sundröm, J
2021-05Reply.Bell, K; Doust, J; McGeechan, K; Horvath, AR; Barratt, A; Hayen, A; Semsarian, C; Irwig, L
2021-02The potential for overdiagnosis and underdiagnosis because of blood pressure variability: a comparison of the 2017 ACC/AHA, 2018 ESC/ESH and 2019 NICE hypertension guidelines.Bell, K; Doust, J; McGeechan, K; Horvath, AR; Barratt, A; Hayen, A; Semsarian, C; Irwig, L
2013-05-04When to remeasure cardiovascular risk in untreated people at low and intermediate risk: Observational studyBell, KJL; Hayen, A; Irwig, L; Takahashi, O; Ohde, S; Glasziou, P